Cape town: Biovac, a prominent South African biopharmaceutical company, has inaugurated its new product development laboratory in Cape Town. This initiative marks a significant advancement towards South Africa’s aspiration for comprehensive vaccine manufacturing capabilities, moving beyond the ‘fill and finish’ stage.
According to South African Government News Agency, the facility is equipped with cutting-edge mRNA technology and advanced research capabilities. This will facilitate the development of innovative drugs and vaccines aimed at combating diseases prevalent in Africa. mRNA vaccines are designed to teach cells how to produce proteins that trigger an immune response, subsequently generating antibodies to protect against future infections.
The opening ceremony featured a keynote address by Dr Nomalungelo Gina, the Deputy Minister of Science, Technology and Innovation. The event also included participation from Mark Suzman, CEO of the Bill and Melinda Gates Foundation, underscoring the foundation’s ongoing collaboration with Biovac to enhance vaccine innovation and accessibility throughout Africa.
Biovac is actively involved in manufacturing vaccines for the Expanded Programme on Immunisation, serving both the private and public sectors. The company receives backing from the government, the Gates Foundation, and the Industrial Development Corporation, further emphasizing its crucial role in strengthening local pharmaceutical manufacturing and preparing the continent for health emergencies with indigenous solutions.